Betterlife Pharma Inc. (TSE:BETR) has released an update.
BetterLife Pharma Inc.’s innovative depression treatment, 2-bromo-LSD, has been spotlighted by Carleton University, with the company’s lead compound BETR-001 poised for human trials in 2024. Additionally, BetterLife has secured $65,000 through convertible debentures to support BETR-001’s development, and plans further private placements, including an investment from CEO Dr. Ahmad Doroudian. These financial maneuvers aim to advance treatments for neuro-psychiatric and neurological disorders.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
